Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) presented nine studies at the annual American Society of Nephrology Kidney Week 2023, reinforcing the safety and effectiveness of LUPKYNISⓇ (voclosporin) for the treatment of adult patients with active Lupus Nephritis (LN). The studies showed that patients treated with LUPKYNISⓇ achieved improvement in histologic activity with stable chronicity scores and no evidence of chronic injury. The data also suggested that LUPKYNISⓇ plus standard of care improved safety and demonstrated earlier reductions in proteinuria compared to a conventional regimen. A post-hoc analysis showed Black patients experienced improved outcomes and better renal response when using LUPKYNISⓇ.